[1]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-WO2022/147465,2022,A1Locationinpatent:Paragraph00797;001220-001222
[2]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-WO2022/147465,2022,A1Locationinpatent:Paragraph00797;001220-001222
766458-70-2
1173205-83-8
13031-60-2
1392804-16-8
27025-25-8
92398-47-5
481704-21-6 | (4S)-4-Hydroxy-D-proline methyl ester, HCl | AA0039R8 | MFCD00135747
4549-02-4 | (3S,8aS)-Hexahydro-3-[(4-hydroxyphenyl)methyl]pyrrolo[1,2-a]pyrazine-1,4-dione | AA0039V6 | MFCD03093467
440627-14-5 | 11-Oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxylic acid | AA0039Z6 | MFCD03019857
1060808-92-5 | 6-Bromo-4-chloronicotinic acid | AA003A2Y | MFCD13189219
54446-36-5 | 4-Bromodiphenylamine | AA003A6M | MFCD07779504
2717-76-2 | Z-Trp-ome | AA003A9S | MFCD06658545
914224-26-3 | 2-Bromo-4-(tert-butoxy)-4-oxobutanoic acid | AA003AF2 | MFCD09032889
53104-16-8 | 3-Bromo-N,N,4-trimethylaniline | AA003AKT | MFCD14529603
125489-21-6 | 1-(3,5-Di-tert-butyl-4-hydroxyphenyl)-1,2-ethanediol | AA003AQW | MFCD32206319
14347-78-5 | (R)-(-)-2,2-Dimethyl-1,3-dioxolane-4-methanol | AA003AVU | MFCD00003213